BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) presented results from two Phase I clinical studies of an intramuscular (i.m.) formulation of peramivir at the Options for the Control of influenza Conference in Toronto, Ontario, Canada. This major international influenza conference is held only once every four years. These studies represent an important component of the company's clinical development program for peramivir, a neuraminidase inhibitor being developed for the treatment of seasonal and potentially life-threatening influenza. Top-line data are summarized as follows: -- A total of 51 healthy adult volunteers received either one of three dose regimens of peramivir or placebo -- Maximum plasma concentrations of peramivir (ranging from approximately 4,000 ng/mL to 15,000 ng/mL) were present as early as 20 minutes after administration -- Peramivir exhibited a long terminal half-life (17.7 to 24.3 hours) -- The bioavailability of single doses of i.m. peramivir is high (>98%) -- Peramivir was well-tolerated in both of these studies Jon P. Stonehouse, Chief Executive Officer of BioCryst said "these findings suggest an excellent safety profile of peramivir when given as an intramuscular injection, and, secondly, the concentrations of peramivir in blood after intramuscular dosing are reassuringly high and are similar to levels after intravenous administration. We look forward to the completion of our ongoing Phase II study of i.m. peramivir in the treatment of acute influenza in outpatients." BioCryst is advancing the clinical development of peramivir under terms of a contract from the U.S. Department of Health and Human Services (DHHS) which on January 4, 2007 awarded BioCryst a $102.6 million, four-year contract to develop peramivir for the treatment of seasonal and life-threatening influenza. Funding from the contract will support Phase II and Phase III product development activities including manufacturing of clinical lots, process validation, clinical studies and other product approval requirements needed for U.S. licensure. BioCryst retains 100% development and commercialization rights to peramivir worldwide other than in Japan and Korea where BioCryst recently established strategic partnerships with Shionogi & Co. in Japan, and Green Cross in Korea. About Peramivir Peramivir is a member of the class of Antiviral Agents that inhibit influenza viral neuraminidase, an enzyme that is essential for the spread of influenza virus within the host. Peramivir is an inhibitor of influenza A and B neuraminidases and certain strains of influenza viruses that may be resistant to available neuraminidase inhibitors but are susceptible to peramivir in laboratory tests. At the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in September, 2006, data were presented showing that injectable formulations of peramivir were safely administered to healthy subjects at daily doses up to approximately 600 mg. At the same meeting, animal data were presented showing peramivir promoted survival in animals infected with highly pathogenic strains of the H5N1 virus. Peramivir injection has received Fast Track designation from US FDA and the availability of an intravenous neuraminidase inhibitor may be important in treating patients hospitalized with severe and potentially life-threatening influenza. The availability of an intramuscular formulation of peramivir could ensure appropriate dosing which may be a concern with currently available oral or inhaled anti-influenza agents. About Influenza The influenza virus causes an acute viral disease of the respiratory tract. Unlike the common cold and some other respiratory infections, seasonal flu can cause severe illness, resulting in life-threatening complications. According to the Centers for Disease Control and Prevention, every year in the United States more than 200,000 people are hospitalized from flu complications, and about 36,000 people die from flu. Most at risk are young children, the elderly, and people with seriously compromised immune systems. Avian influenza A viruses of H5N1 subtype are circulating among birds worldwide, the virus is considered extremely contagious in fowl. It is believed that all species of birds are susceptible to avian influenza, but domestic poultry, including chickens and turkeys, are among the more susceptible to the highly pathogenic strain. According to the World Health Organization, at least 261 people have contracted H5N1 avian influenza, of which at least 157 have died. Almost all of these infections are believed to have resulted from contact with infected poultry. About BioCryst BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine(TM) in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February, 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at

<< Prev	Pharmacy News Home	Next>>